Allergy Thera. Share News (AGY)

Allergy Therapeutics Continues To Perform Well, Revenue Up "Strongly"

LONDON (Alliance News) - Allergy Therapeutics PLC said Tuesday it has continued to perform well, with revenue up "strongly" from the prior year and sales in line with market financial to

Allergy Therapeutics boosted by strong German performance

(Sharecast News) - Biotechnology company Allergy Therapeutics has seen revenues increase throughout the first half of its trading year thanks to an improved market share for its allergy vaccines on the continent.

BlackRock Lowers Allergy Therapeutics Stake Below Threshold (ALLISS)

LONDON (Alliance News) - Allergy Therapeutics PLC said Tuesday that BlackRock Inc lowered its stake in the company to below the 5% threshold.Prior to the deal, BlackRock held a 5.1% in the

Allergy Therapeutics Interim Loss Widens But Germany Pushes Revenue Up

LONDON (Alliance News) - Allergy Therapeutics PLC on Wednesday said its loss widened in the first half of 2018, but revenue rose on strong performance in Germany and a strengthening of the company

Allergy Therapeutics To Raise GBP11 Million Via Share Issue (ALLISS)

LONDON (Alliance News) - Allergy Therapeutics PLC said Thursday that it will raise up to GBP10.6 million via placing and subscription.The pharmaceutical company focused on allergy vaccines

Allergy Therapeutics Reveals Good Results From Dust Mite Allergy Tests

LONDON (Alliance News) - Biotechnology firm Allergy Therapeutics PLC said it will present positive new data on its dust mite allergy treatment at a congress in Germany on Tuesday.Allergy is

Allergy Therapeutics Reports Positive Results From Grass Pollen Study

LONDON (Alliance News) - Allergy Therapeutics PLC said Monday it saw positive results from its grass pollen allergy treatment phase II dose ranging study as it prepares to commence in phase III it

Allergy Therapeutics Gets Positive Indications In Latest MCT Study

LONDON (Alliance News) - Biotechnology firm Allergy Therapeutics PLC on Monday said it has received positive new data in a study investigating its microcrystalline tyrosine-based results, it said,

DIRECTOR DEALINGS: Allergy Therapeutics Non-Executive Lifts Stake

LONDON (Alliance News) - Pharmaceutical company Allergy Therapeutics PLC said Friday Non-Executive Director Tunde Otulana acquired shares on Thursday.Otulana acquired a

Allergy Therapeutics Profit Falls On Costs As Pivotal Year Looms

LONDON (Alliance News) - Allergy Therapeutics PLC said Wednesday half year profit fell due to higher research and development costs, as the company prepares for 2018 clinical

Allergy Therapeutics gets trial go-ahead in Spain

(ShareCast News) - Specialty pharmaceutical company Allergy Therapeutics announced on Tuesday that its Phase I clinical study investigating the safety and tolerability of Acarovac MPL received 'Clinical Trial Application' approval in Spain. The AIM-traded firm said it now expected the formulation to

Allergy Therapeutics' House-Dust Mite Allergy Vaccine Trial Approved

New broad patent strengthens Allergy Therapeutics portfolio

(ShareCast News) - Vaccine-focused pharmaceutical company Allergy Therapeutics announced on Wednesday that the European Patent Office has granted a broad technology patent relating to the its unique microcrystalline tyrosine depot adjuvant manufacturing process. The AIM-traded firm said the patent c

Allergy Therapeutics Granted EU Patent For Microcrystalline Tyrosine

Allergy Therapeutics examines potential of adjuvant portfolio

(ShareCast News) - Allergy Therapeutics will look into potential wider applications for its adjuvant technology after recent clinical research produced encouraging indications about both allergy vaccination and infectious disease applications. Microcrystalline tyrosine (MCT), an aluminium-free depot